Inhibiting ACAT2 may help eliminate heart disease
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Dr. Larry Rudel joins Dr. Larry Kaskel to discuss the enzyme ACAT2 and its confirmed relationship with LDL. Dr. Rudel's new study in mice raises a tantalizing possibility. By inhibiting ACAT2, will we one day be able to eat any kind of fat we want without raising our risk of heart disease?
Overview
Dr. Larry Rudel joins Dr. Larry Kaskel to discuss the enzyme ACAT2 and its confirmed relationship with LDL. Dr. Rudel's new study in mice raises a tantalizing possibility. By inhibiting ACAT2, will we one day be able to eat any kind of fat we want without raising our risk of heart disease?
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Evolving Our View of the Coagulation Cascade and Stroke Management
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
M3: Managing the Cardiometabolic Risk in MASH
Maximizing Adherence and Persistence via Patient Engagement
Love Story: Lipid Education for Women’s Heart Health
Clinical Conundrums in ARIA: Communicating ARIA Risk with Patients Considering Anti-Aβ Therapy
Navigating Myasthenia Gravis in Adolescents and Young Adults
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?